Recently, the FDA approved the use of the thyroid-hormone receptor-beta agonist resmetirom to reduce the risk of the development of cirrhosis in patients with NAFLD, with a demonstrated resolution of NASH in 30% of those receiving the high dose relative to the 10% in the placebo group in phase III trials [122,123]. This evidence concerns the gene THRB and Cirrhosis.